Department of Pathology, UPMC Presbyterian Shadyside, Presbyterian Campus-A610, 200 Lothrop St, Pittsburgh, PA 15213-2582, USA.
Am J Clin Pathol. 2013 Aug;140(2):225-30. doi: 10.1309/AJCP4MXTNQRVOE2T.
To study a subset of lung adenocarcinomas with aberrant HepPar-1 antigen expression.
We performed a clinicopathologic review of 16 cases.
Of 241 primary lung adenocarcinomas tested for expression of the HepPar-1 antigen, 16 (6.6%) were positive. The cases occurred in older smokers with an equal sex distribution. Morphologically, these pulmonary adenocarcinomas had an acinar-predominant architecture, and prominent cribriform growth, with HepPar-1-expressing tumor cells being uniformly columnar with abundant bipolar lightly eosinophilic cytoplasm. HepPar-1 was coexpressed with thyroid transcription factor 1 in 94% of cases. No EGFR mutations were identified, while 31% of cases were positive for KRAS codon 12 mutations.
Although aberrant HepPar-1 expression was frequently seen in tumors with visceral pleural and angiolymphatic invasion, its prognostic significance is uncertain.
研究一组具有异常 HepPar-1 抗原表达的肺腺癌。
我们对 16 例病例进行了临床病理回顾。
在 241 例原发性肺腺癌中检测 HepPar-1 抗原的表达，有 16 例（6.6%）呈阳性。这些病例发生在有吸烟史的老年患者中，性别分布均等。形态上，这些肺腺癌具有腺泡为主的结构，明显的筛状生长，具有 HepPar-1 表达的肿瘤细胞均匀呈柱状，含有丰富的双极嗜酸性细胞质。在 94%的病例中，HepPar-1 与甲状腺转录因子 1 共表达。未发现 EGFR 突变，而 31%的病例 KRAS 密码子 12 突变阳性。
尽管异常 HepPar-1 表达在具有内脏胸膜和血管淋巴管侵犯的肿瘤中经常出现，但它的预后意义尚不确定。
Zotero 插件